Drug Interactions between finasteride and tacrolimus
This report displays the potential drug interactions for the following 2 drugs:
- finasteride
- tacrolimus
Interactions between your drugs
finasteride tacrolimus
Applies to: finasteride and tacrolimus
MONITOR: Coadministration of sirolimus or tacrolimus with other drugs that are also metabolized by CYP450 3A4 may result in elevated plasma concentrations of the macrolide immunosuppressant and/or the coadministered drug(s). The mechanism is decreased drug clearance due to competitive inhibition of CYP450 3A4 activity. Although clinical data are lacking, the possibility of prolonged and/or increased pharmacologic effects of the drugs should be considered.
MANAGEMENT: Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.
References (2)
- (2001) "Product Information. Prograf (tacrolimus)." Fujisawa
- (2001) "Product Information. Rapamune (sirolimus)." Wyeth-Ayerst Laboratories
Drug and food/lifestyle interactions
tacrolimus food/lifestyle
Applies to: tacrolimus
GENERALLY AVOID: Grapefruit and/or grapefruit juice may increase the plasma concentrations of tacrolimus. The proposed mechanism for the interaction is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. Inhibition of hepatic CYP450 3A4 may also contribute. Although clinical data are lacking, this interaction may result in increased risk of serious adverse reactions such as nephro- and neurotoxicity, as well as other adverse effects associated with tacrolimus such as malignancies, infections, diabetes, hyperkalemia, hypertension, and QT prolongation.
GENERALLY AVOID: Alcohol may modify the rate of tacrolimus release from extended release formulations, thereby potentially increasing the risk of serious adverse reactions.
ADJUST DOSING INTERVAL: Coadministration with food decreases the rate and extent of tacrolimus absorption. This effect is greatest after a high-fat meal.
MANAGEMENT: Patients should avoid consumption of food or drink containing grapefruit during treatment with tacrolimus. Concomitant use of tacrolimus, especially extended release formulations, with alcohol should also be avoided. Tacrolimus extended release formulations should be administered on an empty stomach, at least 1 hour before or 2 hours after a meal, and tacrolimus immediate release formulations should be taken consistently every day with or without food.
References (18)
- (2001) "Product Information. Prograf (tacrolimus)." Fujisawa
- Hooks MA (1994) "Tacrolimus, a new immunosuppressant--a review of the literature." Ann Pharmacother, 28, p. 501-11
- (2022) "Product Information. Adoport (tacrolimus)." Sandoz Ltd
- (2024) "Product Information. TACrolimus (Sandoz) (TACrolimus)." Sandoz Pty Ltd
- (2023) "Product Information. Prograf (tacrolimus)." Astellas Pharma US, Inc
- (2023) "Product Information. Astagraf XL (tacrolimus)." Astellas Pharma US, Inc
- (2025) "Product Information. Envarsus XR (tacrolimus)." Veloxis Pharmaceuticals
- (2024) "Product Information. Prograf (tacrolimus)." Astellas Pharma Canada Inc
- (2024) "Product Information. Advagraf (tacrolimus)." Astellas Pharma Canada Inc
- (2024) "Product Information. Envarsus PA (tacrolimus)." Endo Operations LTD
- (2024) "Product Information. Dailiport (tacrolimus)." Sandoz Ltd
- (2025) "Product Information. Prograf (tacrolimus)." Astellas Pharma Ltd
- (2025) "Product Information. Envarsus (tacrolimus)." Chiesi Ltd
- (2025) "Product Information. Advagraf (tacrolimus)." Astellas Pharma Ltd
- (2025) "Product Information. Modigraf (tacrolimus)." Astellas Pharma Ltd
- (2024) "Product Information. Advagraf XL (TACrolimus)." Astellas Pharma Australia Pty Ltd
- (2024) "Product Information. proGRAF (TACrolimus)." Astellas Pharma Australia Pty Ltd
- (2024) "Product Information. TACrolimus XR (Sandoz) (TACrolimus)." Sandoz Pty Ltd
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.